sub:assertion {
d:DB05926 v:identifier "DB05926" ;
v:namespace "drugbank" ;
v:uri "http://bio2rdf.org/drugbank:DB05926" ;
v:x-identifiers.org <
http://identifiers.org/drugbank/DB05926> ;
dv:drugbank-id "DB05926" ;
dv:x-cas <
http://bio2rdf.org/cas:> ;
dct:description "Actyve hormone therapy employs Vyteris' proprietary Actyve(TM) transdermal drug delivery technology, which is positioned to provide a safe and effective method of delivering drugs via a pre-programmed regulating system that mimics the body's natural rhythms, a characteristic important in the delivery of therapeutics for the treatment of infertility. The Company's Actyve(TM) transdermal technology uses an integrated circuit to control a small amount of current that delivers drugs through the skin. This process is called iontophoresis. The two-component system employs a transdermal patch containing the drug and a small battery-powered controller that precisely controls the rate and amount of drug released from the patch. The level of control is intended to mimic IV or infusion pump delivery without needles."@en ;
dct:identifier "drugbank:DB05926" ;
dct:title "Actyve hormone therapy"@en ;
a dv:Drug ;
rdfs:label "Actyve hormone therapy [drugbank:DB05926]"@en ;
rdfs:seeAlso <
http://www.drugbank.ca/drugs/DB05926> .
}